Associated Papers
Patisiran, an RNAi therapeutic for hereditary transthyretin-mediated amyloidosis: Sub-analysis in Taiwanese patients from the APOLLO study.
Lin KP et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi, 2024
Long-term treatment of hereditary transthyretin amyloidosis with patisiran: multicentre, real-world experience in Italy.
Gentile L et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2024
Vutrisiran: a new drug in the treatment landscape of hereditary transthyretin amyloid polyneuropathy.
Planté-Bordeneuve V et al.
Expert Opinion on Drug Discovery, 2024
Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation.
Badri P et al.
Clinical Pharmacokinetics, 2023
Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.
Nie T et al.
Drugs, 2023
Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy.
Dardiotis E et al.
Current Neuropharmacology, 2023
Hereditary Transthyretin Amyloidosis with Polyneuropathy: Monitoring and Management.
Vélez-Santamaría V et al.
International Journal of General Medicine, 2022
Cardiovascular Diseases That Have Emerged From the Darkness.
Maron BJ et al.
Journal of the American Heart Association, 2021
Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis.
Ticau S et al.
Neurology, 2021
Population Pharmacokinetic-Pharmacodynamic Model of Serum Transthyretin Following Patisiran Administration.
Goel V et al.
Nucleic Acid Therapeutics, 2020
Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
Zhang X et al.
Journal of Clinical Pharmacology, 2020
Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis.
Zhang X et al.
Journal of Clinical Pharmacology, 2020
An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis.
Milani P et al.
Expert Opinion on Pharmacotherapy, 2019
Advances in the treatment of hereditary transthyretin amyloidosis: A review.
Gertz MA et al.
Brain and Behavior, 2019
Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis.
Yang J
Expert Review of Clinical Pharmacology, 2019
Tafamidis, a Noninvasive Therapy for Delaying Transthyretin Familial Amyloid Polyneuropathy: Systematic Review and Meta-Analysis.
Zhao Y et al.
Journal of Clinical Neurology (seoul, Korea), 2019
Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment.
Siddiqi OK et al.
Trends in Cardiovascular Medicine, 2018
Recent Advances in Oligonucleotide-Based Therapy for Transthyretin Amyloidosis: Clinical Impact and Future Prospects.
Hayashi Y et al.
Biological & Pharmaceutical Bulletin, 2018
Novel pharmacotherapies for cardiac amyloidosis.
Alexander KM et al.
Pharmacology & Therapeutics, 2017
Update on the clinical utility of an RNA interference-based treatment: focus on Patisiran.
Rizk M et al.
Pharmacogenomics and Personalized Medicine, 2017
First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy.
Adams D et al.
Current Opinion in Neurology, 2016
Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study.
Suhr OB et al.
Orphanet Journal of Rare Diseases, 2015
Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy.
Plante-Bordeneuve V
Journal of Neurology, 2014
[Use of RNAi in the treatment of hereditary amyloidosis due to mutation of transthyretin].
Adams D et al.
Medecine Sciences : M/s, 2014
Novel drugs targeting transthyretin amyloidosis.
Hanna M
Current Heart Failure Reports, 2014
Safety and efficacy of RNAi therapy for transthyretin amyloidosis.
Coelho T et al.
The New England Journal of Medicine, 2013
Recent advances in the treatment of familial amyloid polyneuropathy.
Adams D
Therapeutic Advances in Neurological Disorders, 2013
[Familial amyloid polyneuropathies: therapeutic issues].
Adams D et al.
Bulletin De L'academie Nationale De Medecine, 2012
Evaluation of tafamidis as first-line therapeutic agent for transthyretin familial amyloidotic polyneuropathy.
Buxbaum JN
Degenerative Neurological and Neuromuscular Disease, 2012